Travere Therapeutics Provides Corporate Update and 2021 Outlook
Pipeline of potential first-in-class therapies on track to deliver two pivotal readouts in 2021
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2020 to be approximately $51 million.